Table 1.
Patients’ characteristics by TPV.
| Variable | Lower TPV (<87.5 ml) | Higher TPV (⩾87.5 ml) | Total | Group difference p value |
|---|---|---|---|---|
| N | 187 (92%) | 17 (8%) | 204 | |
| Age (years) | 60.87 ± 14.18 | 69.24 ± 6.95 | 61.57 ± 13.90 | 0.02 |
| BMI (kg/m2) | 28.98 ± 6.37 | 30.38 ± 4.55 | 29.05 ± 6.29 | NS |
| Obese (BMI ⩾ 30) | 45 (24%) | 3 (18%) | 48 (38%) | NS |
| Height (m) | 1.76 ± 0.08 | 1.77 ± 0.06 | 1.76 ± 0.08 | NS |
| CGV (ml) | 17.99 ± 14.03 | 95.21 ± 42.21 | 24.42 ± 27.90 | <0.0001 |
| CGL (mm) | 2.72 ± 0.74 | 5.01 ± 0.86 | 2.91 ± 0.98 | <0.0001 |
| CGW (mm) | 3.46 ± 0.99 | 6.15 ± 0.78 | 3.68 ± 1.23 | <0.0001 |
| CGH (mm) | 3.11 ± 0.88 | 5.68 ± 0.90 | 3.33 ± 1.13 | <0.0001 |
| TPV (ml) | 36.01 ± 18.18 | 125.69 ± 41.13 | 43.48 ± 32.46 | <0.0001 |
| TGL (mm) | 3.44 ± 0.77 | 5.62 ± 0.84 | 3.62 ± 0.98 | <0.0001 |
| TGW (mm) | 4.81 ± 0.76 | 6.56 ± 0.79 | 4.95 ± 0.90 | <0.0001 |
| TGH (mm) | 3.93 ± 0.82 | 6.41 ± 0.60 | 4.13 ± 1.06 | <0.0001 |
| Average capsule length (mm) | 1.04 ± 0.17 | 1.02 ± 0.08 | 1.04 ± 0.16 | NS |
| PZT (mm) | 7.50 ± 2.23 | 5.44 ± 2.43 | 7.32 ± 2.31 | 0.0004 |
| PZV (ml) | 18.02 ± 8.16 | 30.49 ± 16.95 | 19.06 ± 9.77 | <0.0001 |
| PSA (ng/ml) | 11.38 ± 6.70 | 10.26 ± 18.71 | 10.35 ± 17.97 | NS |
| Race | ||||
| Asian | 2 (1%) | 0 (0%) | 2 (1%) | NS |
| White | 154 (93%) | 16 (94%) | 170 (93%) | NS |
| Black | 10 (6%) | 1 (6%) | 11 (6%) | NS |
Values are expressed as column frequencies (%) or means ± SD.
BMI, body mass index; CGH, central gland height; CGL, central gland length; CGV, central gland volume; CGW, central gland width; NS, not statistically significant; PSA, prostate-specific antigen; PZV, peripheral zone volume; PZT, peripheral zone thickness; SD, standard deviation; TGH, total gland height; TGL, total gland length; TGW, total gland width; TPV, total prostate volume.